{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:28:19Z","timestamp":1793964499997,"version":"4.8.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013301","name":"Parkinson's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019736","name":"Farmer Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.medj.2025.100645","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T10:35:39Z","timestamp":1744367739000},"page":"100645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["GLP-1 agonists to slow down Parkinson\u2019s progression? The quest continues"],"prefix":"10.1016","volume":"6","author":[{"given":"Bastiaan R.","family":"Bloem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Macklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Schwarzschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100645_bib1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2025.100645_bib2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3233\/JPD-230363","article-title":"Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative","volume":"14","author":"Wyse","year":"2024","journal-title":"J.\u00a0Parkinsons Dis."},{"key":"10.1016\/j.medj.2025.100645_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ana.26612","article-title":"An Apple a Day to Keep the Parkinson's Disease Doctor Away?","volume":"93","author":"Bloem","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.medj.2025.100645_bib4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/mds.27361","article-title":"Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort","volume":"33","author":"Simuni","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.medj.2025.100645_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/archneurol.2009.295","article-title":"The clinically important difference on the unified Parkinson's disease rating scale","volume":"67","author":"Shulman","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.medj.2025.100645_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26479","article-title":"Bridging the gap between statistical significance and clinical relevance: a systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research","volume":"10","author":"Mishra","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.medj.2025.100645_bib7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/M19-2534","article-title":"Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial","volume":"172","author":"Simuni","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.medj.2025.100645_bib8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3233\/JPD-191648","article-title":"The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease","volume":"9","author":"Stephenson","year":"2019","journal-title":"J.\u00a0Parkinsons Dis."},{"key":"10.1016\/j.medj.2025.100645_bib9","unstructured":"Kumbroch D (2024). FDA Issues \u2018Letter of Support\u2019 Encouraging Use of Synuclein-based Biomarker, \u03b1Syn-SAA, in Clinical Trials for Parkinson\u2019s and Related Diseases. https:\/\/www.michaeljfox.org\/news\/fda-issues-letter-support-encouraging-use-synuclein-based-biomarker-asyn-saa-clinical-trials."},{"key":"10.1016\/j.medj.2025.100645_bib10","first-page":"5825","article-title":"Factors associated with a placebo effect in Parkinson's disease in clinical trials: a meta-analysis","volume":"271","author":"Haji","year":"2024","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.medj.2025.100645_bib11","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jama.2021.10207","article-title":"Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial","volume":"326","author":"Schwarzschild","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2025.100645_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41531-024-00666-6","article-title":"Tackling vascular risk factors as a possible disease modifying intervention in Parkinson's disease","volume":"10","author":"Visser","year":"2024","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.medj.2025.100645_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria","volume":"23","author":"H\u00f6glinger","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2025.100645_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","article-title":"A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research","volume":"23","author":"Simuni","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2025.100645_bib15","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1007\/s13311-020-00904-8","article-title":"Current Perspectives on Aerobic Exercise in People with Parkinson's Disease","volume":"17","author":"Schootemeijer","year":"2020","journal-title":"Neurotherapeutics"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025000728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025000728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:01:41Z","timestamp":1762639301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025000728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2666634025000728"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100645","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 agonists to slow down Parkinson\u2019s progression? The quest continues","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100645"}}